Novartis Purchases Bristol's Consumer Business

The $660 mil. acquisition makes the Swiss firm a "more attractive" Rx-to-OTC switch partner, Novartis Consumer Health CEO Choffat says. Bristol's OTCs include Excedrin, Comtrex, Bufferin, No-Doz.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet